Harmony Biosciences (HRMY) News Today $35.59 +0.03 (+0.08%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 5 at 5:49 AM | marketbeat.comVersor Investments LP Purchases Shares of 18,210 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Versor Investments LP purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 18,210 shares of the company's stock, valued at approximately $54August 28, 2024 | americanbankingnews.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives $41.67 Consensus Target Price from AnalystsAugust 25, 2024 | msn.comHarmony Biosciences Set to Engage at Key Investor ConferencesAugust 25, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Moderate Buy" by AnalystsHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation aAugust 21, 2024 | prnewswire.comHARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESAugust 20, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Hennion & Walsh Asset Management Inc.Hennion & Walsh Asset Management Inc. grew its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 214.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 44,945 shares of the company's stock aftAugust 19, 2024 | seekingalpha.comHarmony Biosciences: Unnoticed Melodies Of Portfolio Growth And Pipeline PotentialAugust 15, 2024 | seekingalpha.comHarmony Biosciences: Advancing An Expanded PipelineAugust 9, 2024 | marketbeat.comCantor Fitzgerald Comments on Harmony Biosciences Holdings, Inc.'s FY2024 Earnings (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2024 earnings per share estimates for shares of Harmony Biosciences in a research note issued to investors on Wednesday, August 7th. Cantor Fitzgerald analyst C. DuncanAugust 7, 2024 | msn.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | markets.businessinsider.comHarmony Biosciences Holdings Sell Rating Affirmed Amid Slowing Patient Growth and Unchanged Revenue GuidanceAugust 6, 2024 | msn.comUpdate: OLPX, HRMY, GLDD and III, August 6August 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Harmony Biosciences on Strong Earnings and Promising Drug Formulation ProspectsAugust 6, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc. (HRMY) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Trading 11.5% Higher Harmony Biosciences (NASDAQ:HRMY) Trading 11.5% HigherAugust 6, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $52.00 target price on shares of Harmony Biosciences in a report on Tuesday.August 6, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 6, 2024 | globenewswire.comHarmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028August 5, 2024 | markets.businessinsider.comHarmony Biosciences earnings preview: what to expectAugust 4, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. reduced its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 1.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 3,628,225 shares of the company's stock after selling 46,539 shares during the period. Vanguard GroAugust 3, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Janus Henderson Group PLCJanus Henderson Group PLC lifted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 1,011.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 185,083 shares of the company's stock aftJuly 31, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Recommendation of "Moderate Buy" from AnalystsHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and seven hJuly 29, 2024 | msn.comHarmony Biosciences to Announce Q2 Financial ResultsJuly 27, 2024 | msn.comPortfolio Change: One Stock To Buy, July 26July 26, 2024 | marketbeat.comFY2024 EPS Estimates for Harmony Biosciences Holdings, Inc. Lowered by Analyst (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at Cantor Fitzgerald cut their FY2024 EPS estimates for shares of Harmony Biosciences in a research note issued to investors on Wednesday, July 24th. Cantor Fitzgerald analyst C. Duncan now forecasts that the coJuly 24, 2024 | finance.yahoo.comHarmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock Is Going Strong: Is the Market Following Fundamentals?July 24, 2024 | finance.yahoo.comHRMY Aug 2024 20.000 put (HRMY240816P00020000)July 23, 2024 | prnewswire.comHARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024July 13, 2024 | marketbeat.comLSV Asset Management Acquires 260,093 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)LSV Asset Management grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 346.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 335,146 shares ofJuly 9, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Trading Up 4.1%Harmony Biosciences (NASDAQ:HRMY) Stock Price Up 4.1%July 6, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation anJuly 3, 2024 | marketbeat.comHedeker Wealth LLC Invests $2.63 Million in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Hedeker Wealth LLC bought a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 78,223 shares of the company's stock, valuedJuly 3, 2024 | marketbeat.comFY2024 Earnings Estimate for Harmony Biosciences Holdings, Inc. Issued By Cantor Fitzgerald (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 EPS estimates for Harmony Biosciences in a research report issued to clients and investors on Monday, July 1st. Cantor Fitzgerald analyst C. Duncan now anticipates thaJuly 2, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Shares Down 2.9% Harmony Biosciences (NASDAQ:HRMY) Stock Price Down 2.9%July 1, 2024 | investorplace.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsJune 30, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Short Interest Up 17.1% in JuneHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 8,130,000 shares, a growth of 17.1% from the May 31st total of 6,940,000 shares. Based on an average trading volume of 383,000 shares, the days-to-cover ratio is presently 21.2 days. Approximately 26.5% of the shares of the stock are sold short.June 25, 2024 | prnewswire.comHARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)June 24, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $52.00 target price on shares of Harmony Biosciences in a report on Monday.June 24, 2024 | investorplace.com7 Biotech Stocks to Buy on the Dip: June 2024June 24, 2024 | prnewswire.comHARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSYJune 21, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Coverage Initiated at CitigroupCitigroup initiated coverage on shares of Harmony Biosciences in a report on Friday. They set a "buy" rating and a $48.00 price objective on the stock.June 7, 2024 | marketbeat.comFranklin Resources Inc. Acquires Shares of 27,136 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Franklin Resources Inc. bought a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 27,136 shares of the company's stock, valued at approximately $876,0June 5, 2024 | prnewswire.comHARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1June 4, 2024 | marketbeat.comDimensional Fund Advisors LP Has $23.79 Million Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Dimensional Fund Advisors LP reduced its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 736,268 shares of the compaJune 3, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Significant Increase in Short InterestHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 7,090,000 shares, an increase of 5.5% from the April 30th total of 6,720,000 shares. Approximately 23.1% of the shares of the company are sold short. Based on an average trading volume of 415,000 shares, the short-interest ratio is presently 17.1 days.May 31, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 28,256 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Charles Schwab Investment Management Inc. boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 9.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,167 shares of the company's stoMay 28, 2024 | prnewswire.comHARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCEMay 20, 2024 | marketbeat.comGreat Lakes Advisors LLC Has $4.56 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Great Lakes Advisors LLC lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 49.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 141,301 shares of the company's stock after selling 139,867 sharesMay 17, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of "Moderate Buy" from AnalystsHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and six haveMay 10, 2024 | marketbeat.comLSV Asset Management Acquires Shares of 75,053 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)LSV Asset Management bought a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 75,053 shares of the company's stock, va Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address The solution to fast food’s wage hike crisis (Ad)Shake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032. Learn more about this much-needed advancement and investment opportunity here. HRMY Media Mentions By Week HRMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRMY News Sentiment▼1.890.55▲Average Medical News Sentiment HRMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRMY Articles This Week▼14▲HRMY Articles Average Week Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Taro Pharmaceutical Industries News OPKO Health News Xencor News Zymeworks News Corcept Therapeutics News Prelude Therapeutics News Axsome Therapeutics News Ascendis Pharma A/S News Intra-Cellular Therapies News Elanco Animal Health News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRMY) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.